ロード中...
1ISG-010 The cost of lacking regulatory clarity for nanosimilars
BACKGROUND: Today up to 23 nanomedicines are approved, and approximately 50 are in clinical development. In the past, first follow-on products also referred to as nanosimilars have entered the European market through the generic approval pathway. Significant differences have been observed in clinica...
保存先:
| 出版年: | Eur J Hosp Pharm |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535185/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.10 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|